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Abstract— Fosmidomycin, which acts through inhibition of 1-deoxy-D-xylulose phosphate reductoisomerase (DXR) in the non-
mevalonate pathway, represents a valuable recent addition to the armamentarium against uncomplicated malaria. In this paper we 
describe the synthesis and biological evaluation of E- and Z-,-unsaturated -aryl-substituted analogues of FR900098, a fosmidomycin 
congener, utilizing a Stille or a Suzuki coupling to introduce the aryl group. In contrast with our expectations based on the promising 
activity earlier observed for several α-substituted fosmidomycin analogues, all synthesized analogues exhibited much lower binding 
affinity for DXR than fosmidomycin. 
With over 500 million clinical cases each year, malaria 
still remains a major threat in the world, as more than 
two million people succumb from the disease each year. 
The high prevalence of the disease is attributed to the 
difficulties in vector control, as well as the increasing 
resistance of Plasmodium falciparum, the main 
causative agent of the disease, towards the commonly 
used antimalarials such as chloroquine. Therefore, new 
antimalarial drugs acting on alternative, yet unexplored 
biochemical pathways are urgently needed. 
 
Recently, the discovery of the mevalonate-independent 
pathway for isoprenoid biosynthesis opened the way for 
new therapeutics to cure malaria, as this alternative 
pathway is absent in humans. Two groups 
simultaneously discovered that fosmidomycin 
effectively inhibits 1-deoxy-D-xylulose 5-phosphate 
reductoisomerase (DXR).1,2 This essential enzyme 
converts 1-deoxy-D-xylulose 5-phosphate (DOXP) to 
2C-methyl-D-erithrytol phosphate (MEP), the second 
step in the non-mevalonate pathway. In recent clinical 
trials fosmidomycin combinations with clindamycin3 or 
artesunate4 were found very efficient in curing P. 
falciparum uncomplicated malaria (Figure 1). 
FR900098, the acetyl congener of fosmidomycin, was 
found to be twice as active as fosmidomycin, both in 
vitro and in a P. vinckei mouse model.2 
For structure-activity relationship analyses of 
fosmidomycin derivatives, various alterations have been 
made, mainly addressing the retrohydroxamate and 
phosphonate moieties.5-9 Comparatively few 
modifications of the carbon spacer have been explored. 
Hence, we recently focused on such type of 
modifications. (Figure 1)  
 
Incorporation of aryl functionalities in -position of the 
phosphonate of fosmidomycin (e.g., 1) or FR900098 
resulted in a markedly enhanced in vitro antiplasmodial 
activity, which proved to be associated to the electron 
withdrawing properties of the aryl substituents.10,11  
Based on a reported prodrug approach,6 Kurz et al. 
systematically investigated the effect of introduction of 
different substituents in α-position of the 
bis(pivaloyloxymethyl) esters of fosmidomycin or 
FR900098.12,13,14 Introduction of an -methyl or -
phenyl substituent afforded analogues, which exhibited 
antiplasmodial activities that came close to that of the 
FR900098 prodrug, while a 3,4-difluorophenyl-
substituted analogue was slightly more potent.12  
 
Consistent with our findings, -aryl-substituted 
fosmidomycin analogues were generally superior to 
their FR900098 homologues. The introduction of an 
ethyl, propyl, isopropyl, dimethyl and hydroxymethyl 
group was associated with a considerable drop in 
antimalarial activity.12 Also -arylmethyl13 or 
phenylethyl14 analogues failed to surpass the activities 
of the -aryl prodrugs. 
Furthermore, rigidification of the carbon spacer by the 
introduction of a cyclopropane15 (as in 2) or 
cyclopentane11 ring, indicated a preferred trans 
geometry for the substituents on these rings for binding 
DXR.  
 
The scope of the present work is to combine both 
features, i.e. rigidification of the carbon spacer (through 
incorporation of an ,-unsaturated bond) and 
introduction of an -aryl substituent. As the ,-double 
bond could occur both in the E- or in the Z-
configuration, these analogues might provide insight in 
the preferred binding conformation of saturated α-
substituted fosmidomycin analogues.  
 
 
Figure 1. Structures of fosmidomycin, FR900098 and analogues under 
study. 
 
The retrosynthetic approaches towards the synthesis of 
the Z- and E-configured analogues of FR900098 are 
briefly depicted in Scheme 1. The synthesis of the Z- 
analogues 3a-e is based on a palladium(0)-catalysed 
Stille-coupling on organotin derivative 5,16 while the 
synthesis of the E-configured analogues 4a,f-g features 
a Suzuki-type cross-coupling on vinylic bromide 6 as a 
key-step.  
 
 
Scheme 1. Retrosynthetic approach towards analogues 3 and 4. 
 
The synthesis of compounds 8a-e in 5 steps from THP-
protected propargyl alcohol 7 via Stille coupling of 5 
(Scheme 2) was recently reported as part of a divergent 
synthetic route towards α-substituted fosmidomycin 
analogues.16 Due to the inherent stereoselectivity of the 
Stille-coupling, only the Z-isomers were obtained. 
 
 
Scheme 2. Reagents and conditions: (a) See Ref. 16; (b) Ar-I, 
Pd2dba3.CHCl3, (2-furyl)3P, CuI, NMP, rt; (c) BCl3, CH2Cl2, -50 °C; (d) 
TMSBr, MeCN, rt; C-18 RP HPLC. 
 
Further elaboration to FR900098 analogues 3a-e 
involved a BCl3-assisted removal of the benzyl 
protecting group from 8a-e. Subsequent cleavage of the 
phosphonate ester groups with TMSBr followed by 
purification by reversed phase HPLC yielded the Z-
configured analogues 3a-e in low to moderate yields.17 
 
A Suzuki-based strategy was chosen for the synthesis of 
the E-,-unsaturated analogues 4a,f-g (Scheme 3). 
First Z--bromo-1-propenyl phosphonate (11) was 
synthesized from diethyl phosphite (10) in two steps.18 
The required Z-configuration was assigned based on the 
3JPH coupling constant (14.2 Hz) in the 1H NMR 
spectrum, which is in accordance with the coupling 
constant typically found for a vinylic proton located cis 
to a phosphonate.19 Radical allylic bromination afforded 
compound 12 in moderate yield. Prior conversion of the 
allylic bromide 12 into iodide 13 via Finkelstein 
reaction was required due to the low reactivity of 
compound 12 in the substitution reaction to yield key 
 
intermediate 6. Conversely, when this substitution 
reaction was applied to iodide 13, protected allylic 
hydroxylamine 6 was obtained in an adequate yield.  
 
 
Scheme 3. Reagents and conditions: (a) see ref. 18; (b) NBS, Ph(COO)2, 
CCl4, reflux; (c) NaI, acetone, rt; (d) BnONHBoc, NaH,DMF, rt. 
 
Optimization of the Suzuki-coupling with a series of 
arylboronic acids (Scheme 4) proved to be troublesome, 
as poor to moderate yields were obtained for 14a,f-g. 
Furthermore, every analogue required different, specific 
conditions for the reaction to occur, in contrast to the 
generally applicable Stille-conditions described above. 
 
 
Scheme 4. Reagents and conditions: (a) PhB(OH)2, Pd(PPh3)4, Na2CO3, 
DME, H2O, 80 °C; (b) (4-CN)PhB(OH)2, Pd(PPh3)4, Na2CO3, THF, H2O, 
80 °C; (c) (3,4-Cl2)PhB(OH)2, Pd(PPh3)4, Na2CO3, dioxane, H2O, 80 °C; 
(d) (i) TFA, CH2Cl2, 0 °C; (ii) Ac2O, pyridine, rt; (e) BCl3, CH2Cl2, -50 
°C; (f) TMSBr, MeCN, rt; NH4OH(aq); CF-11 cellulose chromatography. 
 
To complete the synthesis of analogues 4a,f-g, the Boc-
protecting group of 14a,f-g was first removed, followed 
by in situ acetylation of the free amine to yield the N-
benzyloxyacetamides 15a,f-g. Subsequent removal of 
the benzyl protecting group with BCl3 and cleavage of 
the phosphonate esters yielded the final E-configured 
,-unsaturated, -aryl substituted analogues 4a,f-g, 
which were purified via Whatman CF-11 cellulose 
chromatography, resulting in much improved yields as 
compared to RP-chromatographic purification used for 
3a-e.19,20 Furthermore, application of the same 
deprotection sequence directly on the vinylic bromide 6 
also allowed for the synthesis of the Z-,-unsaturated 
-bromo-substituted analogue 19.  
Because of the difficulties associated with the handling 
of P. falciparum DXR, we investigated the ability of the 
synthesized FR900098 analogues 3a-e, 4a,f-g and 19 to 
inhibit the highly homologous E. coli isozyme. The 
conversion of DOXP to MEP by the enzyme was 
determined in an assay based on the NADPH 
dependency of the reaction and the results are 
summarized in Table 1.21  
 
Table 1. IC50 values  of the synthesized FR900098 analogues against 
recombinant E. coli DXR 
Compound R IC50 E. coli DXR (µM) 
Fosmidomycin  0.034 
FR900098  0.032 
1  0.059 
3a Ph >30 
3b (3-NO2)Ph >30 
3c (4-NO2)Ph 34 
3d 2-thienyl 42 
3e 3-thienyl > 30 
4a Ph 5.7 
4f (3,4-Cl2)Ph 5.5 
4g (4-CN)Ph 16 
19 Br 0.45 
 
Compared to fosmidomycin and FR900098, the Z-
configured unsaturated analogues 3a-e were found to be 
much weaker inhibitors of E. coli DXR, which was 
anticipated considering the previously found preferred 
trans-orientation of the phosphonate and 
retrohydroxamate functionalities in cyclopropyl and 
cyclopentyl fosmidomycin analogues.11,15 
Unexpectedly, in contrast with the active trans-
substituted cyclopropyl derivative 2, also the E-
configured -aryl substituted FR900098 analogues 
4a,f-g displayed poor inhibitory activity towards E. coli 
DXR. Apparently, the combination of an -aryl 
substituent and an ,-unsaturated bond constrains the 
rotational freedom in a way that is unfavorable for 
binding to active site of DXR. It should be noted that 
the relative conformation of two trans-substituents on a 
cyclopropane ring diverges from that of the trans-
substituents in the E-configured analogues 4a,f-g. 
Remarkably, the -bromo derivative 19, capable of 
undergoing electronical interactions with the target 
enzyme, performs much better than analogues 3a-e and 
4a,f-g.   
 
In conclusion, two different divergent procedures for 
the preparation of both Z- and E-unsaturated α-aryl-
 
substituted FR900098 analogues 3 and 4 were 
developed using respectively a Stille and a Suzuki 
coupling as a key step. Unfortunately, with the 
exception of vinylic bromide 19, none of the 
synthesized compounds exhibited submicromolar DXR 
inhibitory activity. 
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